C. Robert, L. Thomas, I. Bondarenko, S. O'day, J. Weber et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, vol.364, p.2517, 2011.

C. Robert, A. Ribas, J. D. Wolchok, F. S. Hodi, O. Hamid et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, vol.384, pp.1109-1126, 2014.

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. J. Grob, C. L. Cowey et al., Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, N Engl J Med, vol.373, pp.23-34, 2015.

O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, p.134, 2013.

J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi et al., Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer, J Clin Oncol, vol.33, pp.4015-4037, 2015.

A. Patnaik, S. P. Kang, D. Rasco, K. P. Papadopoulos, J. Elassaiss-schaap et al., Phase I Study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors, Clin Cancer Res, vol.21, pp.4286-93, 2015.

N. A. Rizvi, J. Mazières, D. Planchard, T. E. Stinchcombe, G. K. Dy et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-65, 2015.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, pp.2018-2046, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-158, 2015.

S. N. Gettinger, L. Horn, L. Gandhi, D. R. Spigel, S. J. Antonia et al., Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, vol.33, pp.2004-2016, 2015.

D. F. Mcdermott, C. G. Drake, M. Sznol, T. K. Choueiri, J. D. Powderly et al., Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab, J Clin Oncol, vol.33, pp.2013-2033, 2015.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, vol.372, pp.320-350, 2015.

S. L. Topalian, M. Sznol, D. F. Mcdermott, H. M. Kluger, R. D. Carvajal et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, vol.32, p.1020, 2014.

S. M. Ansell, A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott et al., PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, vol.372, pp.311-320, 2015.

R. J. Motzer, B. I. Rini, D. F. Mcdermott, B. G. Redman, T. M. Kuzel et al., Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J Clin Oncol, vol.33, pp.1430-1437, 2015.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 Blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, pp.2509-2529, 2015.

M. A. Postow, J. Chesney, A. C. Pavlick, C. Robert, K. Grossmann et al., Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, vol.372, pp.2006-2023, 2015.

C. Robert, J. Schachter, G. V. Long, A. Arance, J. J. Grob et al., Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, vol.372, pp.2521-2553, 2015.

J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi et al., Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, vol.369, p.122, 2013.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1666, 2015.

T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nat Immunol, vol.14, pp.1212-1220, 2013.

M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008.

C. Granier, S. Karaki, H. Roussel, C. Badoual, T. Tran et al., Cancer immunotherapy: rational and recent breakthroughs, Rev Med Interne, issue.16, pp.30413-30414, 2016.

J. Naidoo, D. B. Page, B. T. Li, L. C. Connell, K. Schindler et al., Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, vol.26, p.2375, 2015.

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.27, pp.559-74, 2016.

A. Bertrand, M. Kostine, T. Barnetche, M. E. Truchetet, and T. Schaeverbeke, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Med, vol.13, p.211, 2015.

P. Polat and P. D. Donofrio, Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer: noteworthy cases, Muscle Nerve, vol.54, p.507, 2016.

K. Lau, A. Kumar, I. H. Yang, and R. J. Nowak, Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab: MG exacerbation after pembrolizumab, Muscle Nerve, vol.54, pp.157-61, 2016.

A. I. Loochtan, M. S. Nickolich, and L. D. Hobson-webb, Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer, Muscle Nerve, vol.52, pp.307-315, 2015.

G. Jour, I. C. Glitza, R. M. Ellis, C. A. Torres-cabala, M. T. Tetzlaff et al., Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions: bullous skin toxicities from anti-PD-1 antibody therapy, J Cutan Pathol, vol.43, pp.688-96, 2016.

J. W. Vandiver, Z. Singer, and C. Harshberger, Severe hyponatremia and immune nephritis following an initial infusion of nivolumab, Target Oncol, vol.11, pp.553-559, 2016.

E. Hansen, D. Sahasrabudhe, and L. Sievert, A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome, Cancer Immunol Immunother, vol.65, pp.765-772, 2016.

Y. Z. Alabed, A. Aghayev, and C. Sakellis, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT, Clin Nucl Med, vol.40, pp.528-537, 2015.

F. Danlos, C. Pagès, B. Baroudjian, L. Vercellino, M. Battistella et al., Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma, Chest, vol.149, pp.133-139, 2016.

V. H. Koelzer, S. I. Rothschild, D. Zihler, A. Wicki, B. Willi et al., Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study, J Immunother Cancer, vol.4, p.13, 2016.

H. Läubli, C. Balmelli, M. Bossard, O. Pfister, K. Glatz et al., Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma, J Immunother Cancer, vol.3, issue.1, 2016.

B. Garel, N. Kramkimel, A. Trouvin, C. Frantz, and N. Dupin, Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma, Joint Bone Spine, 2016.

M. M. Chan, R. F. Kefford, M. Carlino, A. Clements, and N. Manolios, Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma, J Immunother, vol.38, pp.37-46, 2015.

J. Salmon, I. Lambrecht, P. Brochot, and F. Grange, A case of arthritis under pembrolizumab, Joint Bone Spine, 2016.

R. Nair, S. Gheith, and S. G. Nair, Immunotherapy-associated hemolytic anemia with pure red-cell aplasia, N Engl J Med, vol.374, pp.1096-1103, 2016.

B. Y. Kong, K. P. Micklethwaite, S. Swaminathan, R. F. Kefford, and M. S. Carlino, Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma, Melanoma Res, vol.26, pp.202-206, 2016.

S. Kanameishi, A. Otsuka, Y. Nonomura, A. Fujisawa, Y. Endo et al., Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells, Ann Oncol, vol.27, pp.546-553, 2016.

L. C. Cappelli, A. K. Gutierrez, A. N. Baer, J. Albayda, R. L. Manno et al., Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab, Ann Rheum Dis, vol.76, pp.43-50, 2017.

M. Ishikawa and K. Oashi, Case of hypophysitis caused by nivolumab, J Dermatol, vol.44, pp.109-119, 2017.

M. Nishino, A. Giobbie-hurder, H. Hatabu, N. H. Ramaiya, and F. S. Hodi, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis, JAMA Oncol, vol.2, pp.1607-1623, 2016.

G. Carlos, R. Anforth, S. Chou, A. Clements, and P. Fernandez-peñaspe?peñas, A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab, Melanoma Res, vol.25, pp.265-273, 2015.

S. Hwang, G. Carlos, S. Chou, D. Wakade, M. S. Carlino et al., Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies, Melanoma Res, vol.26, pp.413-419, 2016.

K. M. Beck, J. Dong, L. J. Geskin, V. P. Beltrani, R. G. Phelps et al., Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid, J Immunother Cancer, vol.4, p.20, 2016.

S. M. Corsello, A. Barnabei, P. Marchetti, D. Vecchis, L. Salvatori et al., Endocrine side effects induced by immune checkpoint inhibitors, J Clin Endocrinol Metab, vol.98, p.1361, 2013.

C. Gaudy, C. Clévy, S. Monestier, N. Dubois, Y. Préau et al., Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes, Diabetes Care, vol.38, pp.182-185, 2015.

J. Hughes, N. Vudattu, M. Sznol, S. Gettinger, H. Kluger et al., Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy, Diabetes Care, vol.38, pp.55-62, 2015.

M. Nishino, N. H. Ramaiya, M. M. Awad, L. M. Sholl, J. A. Maattala et al., PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course, Clin Cancer Res, 2016.

C. F. Friedman, T. A. Proverbs-singh, and M. A. Postow, Treatment of the immunerelated adverse effects of immune checkpoint inhibitors: a review, JAMA Onco, 2016.

V. R. Belum, B. Benhuri, M. A. Postow, M. D. Hellmann, A. M. Lesokhin et al., Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor, Eur J Cancer, vol.60, pp.12-25, 2016.

A. N. Shoustari, M. A. Postow, T. Z. Horvat, N. G. Adel, T. Dang et al., Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events, ASCO Annual Meeting Proceedings, vol.33, 2015.

J. D. Wolchok, A. Hoos, S. O'day, J. S. Weber, O. Hamid et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009.

F. S. Hodi, W. J. Hwu, R. Kefford, J. S. Weber, A. Daud et al., Evaluation of immune-related response criteria and recist v1.1 in patients with advanced melanoma treated with pembrolizumab, J Clin Oncol, vol.34, pp.1510-1517, 2016.

C. Kyi, R. D. Carvajal, J. D. Wolchok, and M. A. Postow, Ipilimumab in patients with melanoma and autoimmune disease, J Immunother Cancer, vol.2, p.35, 2014.

A. D. Bostwick, A. K. Salama, and B. A. Hanks, Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis, J Immunother Cancer, vol.3, p.19, 2015.

E. J. Gettings, C. T. Hackett, and T. F. Scott, Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma, Mult Scler, vol.21, p.670, 2015.

D. B. Johnson, R. J. Sullivan, P. A. Ott, M. S. Carlino, N. I. Khushalani et al., Ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, JAMA Oncol, vol.2, pp.234-274, 2014.

L. V. Maul, M. Weichenthal, K. C. Kähler, and A. Hauschild, Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease, J Immunother, vol.39, pp.188-90, 2016.

B. Squibb, Immune-mediated adverse reactions management guide, 2015.

. Merck, A guide to monitoring patients during treatment with Keytruda, 2015.

C. Boutros, A. Tarhini, E. Routier, O. Lambotte, F. L. Ladurie et al., Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol, vol.13, pp.473-86, 2016.

T. K. Eigentler, J. C. Hassel, C. Berking, J. Aberle, O. Bachmann et al., Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev, vol.45, pp.7-18, 2016.

M. A. Postow, Managing immune checkpoint-blocking antibody side effects, 2015.

T. Z. Horvat, N. G. Adel, T. O. Dang, P. Momtaz, M. A. Postow et al., Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial sloan kettering cancer center, J Clin Oncol, vol.33, p.3193, 2015.

J. S. Weber, J. C. Yang, M. B. Atkins, and M. L. Disis, Toxicities of immunotherapy for the practitioner, J Clin Oncol, vol.33, pp.2092-2101, 2015.

L. Cooley, C. Dendle, J. Wolf, B. W. Teh, S. C. Chen et al., Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, Intern Med J, vol.2014, pp.1350-63

S. Pascolo, Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies, Eur J Pharmacol, vol.771, pp.139-183, 2016.

A. Brunot, Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients, J Clin Oncol, vol.34, 2016.

A. J. Minn and E. J. Wherry, Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling, Cell, vol.165, pp.272-277, 2016.

A. Eid, R. Razavi, G. Mkrtichyan, M. Janik, J. Khleif et al., Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed, Cancer Immunol Res, vol.4, pp.377-82, 2016.

P. A. Prieto, A. Reuben, Z. A. Cooper, and J. A. Wargo, Targeted therapies combined with immune checkpoint therapy, Cancer J Sudbury Mass, vol.22, pp.138-184, 2016.

A. Ribas, F. S. Hodi, M. Callahan, C. Konto, and J. Wolchok, Hepatotoxicity with combination of vemurafenib and ipilimumab, N Engl J Med, vol.368, p.1365, 2013.

A. Salama, M. A. Postow, and J. K. Salama, Irradiation and immunotherapy: from concept to the clinic, Cancer, vol.122, pp.1659-71, 2016.

S. Aspeslagh, S. Postel-vinay, S. Rusakiewicz, J. Soria, L. Zitvogel et al., Rationale for anti-OX40 cancer immunotherapy, Eur J Cancer Oxf Engl, pp.50-66, 1990.

R. Serre, S. Benzekry, L. Padovani, C. Meille, N. André et al., Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy, Cancer Res, vol.76, pp.4931-4971, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01336779

H. E. Kohrt, P. C. Tumeh, D. Benson, N. Bhardwaj, J. Brody et al., Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immunooncology clinical trials, J Immunother Cancer, vol.4, p.15, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01440327

J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, pp.5064-74, 2014.

W. B. Breunis, E. Tarazona-santos, C. R. Kiley, M. Rosenberg, S. A. Chanock et al., Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade, J. Immunother, vol.31, pp.586-90, 2008.

P. Queirolo, A. Morabito, S. Laurent, S. Lastraioli, P. Piccioli et al., Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study, Cancer Invest, vol.31, pp.336-381, 2013.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer Oxf Engl, pp.139-187, 1990.

L. Spain, J. Larkin, and J. Martin-liberal, Determining predictive factors for immune checkpoint inhibitor toxicity: response to letter to the editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome, Cancer Immunol Immunother, vol.65, pp.765-772, 2016.

K. Dubin, M. K. Callahan, B. Ren, R. Khanin, A. Viale et al., Intestinal microbiome analyses identify melanoma patients at risk for checkpointblockade-induced colitis, Nat Commun, vol.7, p.10391, 2016.

K. Schindler, K. Harmankaya, and D. Kuk, Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, J Clin Oncol, vol.32, issue.5s, 2014.

S. H. Jaber, E. W. Cowen, L. R. Haworth, S. L. Booher, D. M. Berman et al., Skin reactions in a subset of patients with stage IV melanoma treated with anticytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent, Arch Dermatol, vol.142, p.166, 2006.

M. K. Callahan, A. Yang, and S. Tandon, Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis, J Clin Oncol, 2011.

G. Manson, J. Norwood, A. Marabelle, H. Kohrt, and R. Houot, Biomarkers associated with checkpoint inhibitors, Ann Oncol, vol.27, pp.1199-206, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01359396

V. Shahabi, D. Berman, S. D. Chasalow, L. Wang, Z. Tsuchihashi et al., Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events, J Transl Med, vol.11, p.75, 2013.

X. Mariette, J. Gottenberg, P. Ravaud, and B. Combe, Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries, Rheumatol Oxf Engl, vol.50, pp.222-231, 2011.